John is a Partner at Kindred Capital. Before to turning to the ‘dark side’ of investing, John was cofounder and CEO of CCG.ai, a Y-Combinator backed precision oncology company which exited to Dante Labs in 2019. And prior to this, John was a scientist focussed on cancer research, spending time in industry (MedImmune) and academia (Universities of Glasgow and Cambridge). John has 20+ publications, 2000+ citations, a PhD from the University of Cambridge, an MBA from Quantic and an MSci from the University of Glasgow. In 2018 he was named to Forbes 30 under 30 and in 2020 made a Fellow of the Royal Society of Biology.